Recombinant Human CD38 Protein
- Known as:
- Recombinant Human CD38 Protein
- Catalog number:
- cd-772
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Proxinobio
- Gene target:
- Recombinant Human CD38 Protein
Related genes to: Recombinant Human CD38 Protein
- Gene:
- CD38 NIH gene
- Name:
- CD38 molecule
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 4p15.32
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2014-11-18
Related products to: Recombinant Human CD38 Protein
Related articles to: Recombinant Human CD38 Protein
- Anti-CD38 monoclonal antibodies have demonstrated rapid responses in immune thrombocytopenia, with response rates across several agents ranging from moderate to high. However, the durability of these responses after treatment discontinuation appears to vary. The therapeutic effects of anti-CD38 antibodies likely extend beyond depletion of CD38 plasma cells and may involve broader modulation of the immune system. - Source: PubMed
Publication date: 2026/04/23
Ghanima WaleedHou Yu - Daratumumab is an anti-CD38 monoclonal antibody that has shown clinical benefit in both relapsed/refractory as well as newly diagnosed multiple myeloma (MM). Although daratumumab is very well-tolerated, randomized clinical trial data have consistently demonstrated an increased risk of infection, particularly along the respiratory tract, in patients receiving daratumumab. CD38 is present on healthy plasma cells, and their destruction can lead to hypogammaglobulinemia (HGG). In this study, we retrospectively reviewed all patients with MM treated with daratumumab and intravenous immunoglobulin (IVIG) at our institution from 2015-2019. The primary endpoints were the incidence rate ratios (IRR) of all-grade infections and grade 3-4 infections per patient-year during IVIG versus observation. In addition, a separate reference group of MM patients who were treated with daratumumab but never received IVIG was identified to establish baseline infection rates and to identify differences in baseline characteristics among patients who were selected to receive IVIG. A total of 43 patients received daratumumab and IVIG, primarily in the relapsed/refractory setting. All patients had HGG during treatment with daratumumab, with most (81%) experiencing moderate HGG (IgG. - Source: PubMed
Publication date: 2026/04/23
Lancman GuidoSastow DahnielAslanova MiniraMoshier ErinCho Hearn JayJagannath SundarParekh SamirRichard ShambaviRichter JoshuaRodriguez CesarRossi AdrianaSanchez LarysaThibaud SantiagoChari Ajai - Dyslipidemia can modify the function and phenotype of adipose tissue macrophages. Accumulated evidence suggests that metabolically activated (MMe) macrophages perform both detrimental and beneficial functions in adipose tissue. However, no studies evaluating their role in adipogenesis have been performed. Here, we combine in vitro assays with flow cytometry to characterize the adipose tissue macrophage populations of 32 specimens from patients with dyslipidemia and control subjects, and determine the role of MMe macrophages in the differentiation of primary human preadipocytes. We observed that the increase of MMe macrophages from adipose tissue is influenced by dyslipidemia, but the frequency of M1 and M2 macrophages did not differ when comparing both study groups. We found that MMe macrophages from dyslipidemic patients promote more adipogenic differentiation of preadipocytes compared with those from control subjects; this effect can be attributed to a mechanism governed by soluble factors and cell contact. We also observed that CD38 is expressed on CD14CD80CD68 (M1), CD14CD206CD163 (M2) and MMe macrophages from adipose tissue, but a higher frequency of CD38 macrophages with MMe phenotype was found compared with M2. In addition, we observed a positive trend between the frequency of CD38 MMe macrophages and age of dyslipidemic patients. This study demonstrates that MMe macrophages promote the differentiation of preadipocytes and this effect is favored in dyslipidemia conditions. - Source: PubMed
Publication date: 2026/04/22
Martínez-Shio Elena BereniceÁlvarez-de León Leobardo EmmanuelRamírez-Segovia Silvia GuadalupeRamírez-Torres RicardoMartínez-Wagner RogelioCastillo-Martín Del Campo Claudia GuadalupeGalicia-Cruz Othir GidaltiMonsiváis-Urenda Adriana Elizabeth - Acute lung injury (ALI) is a serious inflammatory condition caused by several insults, including LPS-induced immunity dysregulation, among others. In vitro and in vivo models are used to study the protective effect of Naftidrofuryl (NAF) against LPS-induced lung injury. - Source: PubMed
Publication date: 2026/04/20
Bahashwan Abdulrahman SEl-Shoura Ehab A MSaad Hebatallah MZaafar Dalia - Pulmonary hypertension (PH) is a severe progressive disease characterised by elevated pulmonary vascular resistance and right ventricular hypertrophy. Increasing evidence has highlighted the vital role of nicotinamide adenine dinucleotide (NAD) metabolism in cardiovascular disease. However, the role of NAD metabolism-related genes (NMRGs) in PH remains unclear. In this study, we aimed to identify novel NMRGs as biomarkers in PH. - Source: PubMed
Publication date: 2026/04/07
Chu YananYang JinxiuYe TianxinYu FangcongWang QianZhuo Jingming